Projects funded by the NCN
The use of olaparib and ATR / CHK1 kinase inhibitors as a targeted anti-cancer therapy based on synthetic lethality
2019/34/E/NZ7/00056
Keywords:
ATR inhibitor CHK1 inhibitor DNA damage response drug resistance homologous recombination olaparib ovarian cancer
Descriptors:
- NZ7_12: Prevention of human diseases
- NZ7_14: Pharmacy, pharmacotherapy, pharmacology
- NZ1_1: Molecular biology
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska
woj. łódzkie
Principal investigator (from the host institution):
Number of co-investigators in the project: 8
Call: SONATA BIS 9 - announced on 2019-06-17
Amount awarded: 1 999 020 PLN
Project start date (Y-m-d): 2020-07-01
Project end date (Y-m-d): 2024-06-30
Project duration:: 48 months (the same as in the proposal)
Project status: Project completed
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.